[[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, Monophenylester

We are [[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, Monophenylester CAS:379270-35-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: [[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, Monophenylester
CAS.NO:   379270-35-6
Synonyms:
9-[(R)-2-(phenylphosphonomethoxy)propyl]adenine
Phosphonic acid, P-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, monophenyl ester
Phenyl hydrogen ({[(2R)-1-(6-amino-9H-purin-9-yl)-2-propanyl]oxy}methyl)phosphonate
phenyl hydrogen {[[(R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy]methyl}phosphonate
[[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, Monophenylester
phenylydrogen((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl) phosphonate
Phenyl hydrogen [(R)-1-(6-amino-9H-purin-9-yl)propan-2-yloxy]methylphosphonate

Molecular Formula: C15H18N5O4P
Molecular Weight:   363.30800

Physical and Chemical Properties:
Density: 1.5±0.1 g/cm3
Boiling point:610.1±65.0 °C at 760 mmHg
Melting point: /
Flash point: 322.8±34.3 °C
Refractive index: 1.685

Specification:
Appearance:  White powder
Purity:≥99.0%
Water:0.5% Max.
Sulfated ash:0.1% Max.
Total Impurity:0.5% Max.

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:
Storage:2°C-8°C.Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 
Intermediates of Tenofovir disoproxil fumarate CAS:202138-50-9.

Related News: “With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.”2-Bromo-3-Fluoroaniline CAS:111721-75-6 “With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.”2-(2-chloroethoxy)-N-(oxomethylidene)benzenesulfonamide “With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.”7-Chloro-5-phenyl-1H-benzo[e]-[1,4]diazepine-2(3H)-thione The mode of cooperation between domestic API companies and large international companies can lower the export threshold.The mode of cooperation between domestic API companies and large international companies can lower the export threshold.